Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

被引:0
|
作者
Zhang, Xinyu [1 ,2 ,3 ]
Cao, Chao [1 ,2 ]
Zheng, Fei [1 ,2 ]
Liu, Chang [1 ,2 ]
Tian, Xiuqing [1 ,2 ,3 ]
机构
[1] Shandong First Med Univ, Affiliated Hosp 1, Dept Cardiol, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, 6699 Qingdao Rd, Jinan City 250117, Peoples R China
关键词
GLP-1; RAs; Cardiovascular; Type; 2; diabetes; Ischemic cardiomyopathy; Diabetic cardiomyopathy; Heart failure; GLUCAGON-LIKE PEPTIDE-1; PANCREATIC BETA-CELL; IMPROVING MITOCHONDRIAL-FUNCTION; LEFT-VENTRICULAR PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; INSULIN-SECRETION; EJECTION FRACTION; CONSCIOUS DOGS; BLOOD-PRESSURE;
D O I
10.1007/s10557-025-07670-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundGlucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice.ObjectiveThis review aims to comprehensively summarize the role of GLP-1 RAs in the management of diabetes mellitus (DM) and cardiovascular disease (CVD), with a particular emphasis on the underlying signal transduction pathways and their therapeutic potential.MethodsA comprehensive review was carried out through literature research.Results and DiscussionIn pancreatic beta-cells, GLP-1 RAs regulate the secretion of insulin and glucagon in a glucosedependent manner by influencing signaling pathways such as cAMP, PI3K, and MAPK. They also contribute to the regulation of blood glucose levels by promoting the proliferation of beta-cells and inhibiting apoptosis in these cells. Recent comprehensive studies have also demonstrated the favorable impact of GLP-1 RAs on cardiovascular wellbeing. In addition to the cardiovascular protection afforded by glucose metabolism regulation, a large body of evidence from animal and cellular studies has corroborated the beneficial effects of GLP-1 RAs on conditions such as heart failure (HF), hypertension, and ischemic cardiomyopathy. These benefits are mainly attributed to the alleviation of inflammatory responses, reduction of oxidative stress, and prevention of cell apoptosis. Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients.ConclusionGLP-1 RAs play an important role in the management of both diabetes and cardiovascular diseases. They show potential therapeutic value through the modulation of multiple signal transduction pathways. However, there may still be some issues in practical applications that require further research and resolution.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
    Holst, Jens Juul
    Seino, Yutaka
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 85 (01) : 1 - 3
  • [32] The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
    van Baar, Michael J. B.
    van der Aart, Annemarie B.
    Hoogenberg, Klaas
    Joles, Jaap A.
    Heerspink, Hiddo J. L.
    van Raalte, Daniel H.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [33] GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice
    Coke, Lola A.
    Deedwania, Prakash C.
    Hinnen, Debbie
    Magwire, Melissa
    Miller, Nancy H.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2022, 34 (02) : 418 - 440
  • [34] The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
    von Scholten, Bernt Johan
    Kreiner, Frederik Flindt
    Rasmussen, Soren
    Rossing, Peter
    Idorn, Thomas
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [35] GLP-1 receptor agonists and cardiovascular protection: A class effect or not?
    Scheen, Andre J.
    DIABETES & METABOLISM, 2018, 44 (03) : 193 - 196
  • [36] GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time
    Caruso, Irene
    Cignarelli, Angelo
    Laviola, Luigi
    Giorgino, Francesco
    DIABETES CARE, 2022, 45 (02) : E30 - E31
  • [37] Prescription of GLP-1 receptor agonists in hospitalized cardiovascular patients
    Hofer, F.
    Zelniker, T. A.
    Koller, L.
    Kazem, N.
    Schweitzer, R.
    Sulzgruber, P.
    Niessner, A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S248 - S248
  • [38] GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
    Lorber, Daniel
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (04) : 238 - 249
  • [39] GLP-1 receptor agonists and cardiovascular outcome trials: An update
    Andrikou, Eirini
    Tsioufis, Costas
    Andrikou, Ioannis
    Leontsinis, Ioannis
    Tousoulis, Dimitrios
    Papanas, Nikolaos
    HELLENIC JOURNAL OF CARDIOLOGY, 2019, 60 (06) : 347 - 351
  • [40] GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis
    Standl, Eberhard
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (10): : 741 - 743